Suppr超能文献

人血浆中一种新型凝血酶肝素依赖性抑制剂的检测

Detection of a new heparin-dependent inhibitor of thrombin in human plasma.

作者信息

Tollefsen D M, Blank M K

出版信息

J Clin Invest. 1981 Sep;68(3):589-96. doi: 10.1172/jci110292.

Abstract

We have demonstrated that human plasma contains a heparin-dependent inhibitor of thrombin that is distinguishable from antithrombin III (AT III). When a 1:50 dilution of plasma was incubated with greater than or equal to 0.01 U/ml heparin and 1 U/ml 125I-thrombin, the labeled thrombin B-chains became incorporated into two complexes of Mr-96,000 and Mr-85,000 that were separated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate and beta-mercaptoethanol. Neither complex was detectable at heparin concentrations less than 0.01 U/ml. When a limiting amount of 125I-thrombin was present, the proportion of radioactivity incorporated into each of the two complexes varied with the heparin concentration. Thus, the Mr-85,000 complex predominated at 0.01-5 U/ml heparin, whereas the Mr-96,000 complex predominated at 5-100 U/ml heparin. The Mr-85,000 complex reacted with antibodies to human AT III and comigrated with the purified thrombin-AT III complex. The Mr-96,000 complex did not react with antibodies to AT III or to alpha 1-antitrypsin, and it was detected in normal quantities after incubating 125I-thrombin with plasma immunodepleted of AT III, alpha 2-antiplasmin, alpha 2-macroglobulin, C1 inactivator, alpha 1-antichymotrypsin, or inter-alpha-trypsin inhibitor. The protein that combines with thrombin to form the Mr-96,000 complex was estimated to be present at a minimum concentration of 90 +/- 26 micrograms/ml (mean +/- SD) in identical to any of the known plasma protease inhibitors and that at relatively high heparin concentrations in vitro it reacts with thrombin more rapidly than does AT III.

摘要

我们已经证明,人血浆中含有一种依赖肝素的凝血酶抑制剂,它与抗凝血酶III(AT III)不同。当将1:50稀释的血浆与≥0.01 U/ml肝素和1 U/ml 125I-凝血酶一起孵育时,标记的凝血酶B链会形成两种分子量分别为96,000和85,000的复合物,在十二烷基硫酸钠和β-巯基乙醇存在下通过聚丙烯酰胺凝胶电泳进行分离。在肝素浓度低于0.01 U/ml时,这两种复合物均无法检测到。当存在限量的125I-凝血酶时,掺入两种复合物中每种的放射性比例随肝素浓度而变化。因此,在0.01 - 5 U/ml肝素时,分子量85,000的复合物占主导,而在5 - 100 U/ml肝素时,分子量96,000的复合物占主导。分子量85,000的复合物与抗人AT III抗体反应,并与纯化的凝血酶-AT III复合物共迁移。分子量96,000的复合物不与AT III或α1-抗胰蛋白酶抗体反应,并且在用AT III、α2-抗纤溶酶、α2-巨球蛋白、C1灭活剂、α1-抗糜蛋白酶或α-胰蛋白酶间抑制剂免疫去除血浆后与125I-凝血酶孵育,该复合物仍能以正常量检测到。与凝血酶结合形成分子量96,000复合物的蛋白质估计以最低浓度90±26微克/毫升(平均值±标准差)存在,不同于任何已知的血浆蛋白酶抑制剂,并且在体外相对高的肝素浓度下,它与凝血酶的反应比AT III更快。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24e2/370838/26160f0072e5/jcinvest00473-0020-a.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验